Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and T-cell engagers.
Earnings call Q1 2026 revenue declined 3.1% year-over-year to CAD 120.1M, reflecting customer caution and variability in hardware and services. Adjusted EBITDA margin remained strong at 25.9%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results